← Evidence map

ArticleCancer2024

Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study".

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study". | OpenQuestion